Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Pyoderma Gangrenosum

In brief

A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum

Key facts

Study ID
NCT05964413
Run by
InflaRx GmbH
People needed
54
Starts
2023-11-01
Expected to finish
2025-07-11
Last updated by the study team
2025-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.